Development of regional programs to speed treatment of stroke

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


The pathophysiology of ischemic stroke dictates that treatments be administered shortly after symptom onset to be beneficial. Intravenous tissue plasminogen activator is the only drug proven to be effective in stroke; it is approved for administration within a 3-hour window. To optimize the number of potential candidates for thrombolytic therapy, patients and families must understand the symptoms and signs of stroke and how to respond. Emergency medical services and emergency departments also must be prepared for rapid evaluation to determine if a patient is appropriate for reperfusion therapy. Due to a lack of stroke specialists in many communities, some hospitals may not be prepared to provide intravenous thrombolytic therapy around the clock, and time lost transporting patients to tertiary centers may mitigate the benefits of thrombolysis. Telestroke may be the best alternative in this scenario, extending acute stroke therapies to patients who would otherwise not receive treatment.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalCurrent neurology and neuroscience reports
Issue number1
StatePublished - Jan 2008

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Development of regional programs to speed treatment of stroke'. Together they form a unique fingerprint.

Cite this